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Abstract
Vitamin D is synthesized within skin followed by the peripheral maturation in liver and
kidneys. Vitamin D is most essential secosteroid produced its systemic functions via
complex with steroid/thyroid nuclear receptor called vitamin D receptor (VDR). The
binding of the vitamin D3 to VDR causes conformational changes that permit VDR-RXR
heterodimer  formation  and  VDR/  SRC-1  (transcriptional  co-activator  proteins)
interactions.  Functional  expression  and  nuclear  activation  of  VDR  is  necessary  to
produce its effects upon binding with vitamin D response element (VDRE) on target
gene where it causes transcriptional activation resulting in the prevention of breast
cancer  by  inhibiting  proliferation,  impeding  differentiation  and  stimulating  pro-
apoptosis. Season, latitude, pigmentation of skin, aging, sunscreen use, obesity, and
smoking all affect the production of vitamin D. In case of vitamin D deficiency or VDR
gene polymorphisms, vitamin D responses are altered and probably are involved in the
risk of breast cancer. Since many epidemiological,  observational and interventional
studies  have  been  done  to  illustrate  the  role  of  vitamin  D  and  its  receptor  gene
polymorphism in  breast  cancer  development  but  controversial  findings  have been
observed. Therefore, the role of vitamin D and its receptor gene polymorphisms in
development of breast cancer are still a matter of discussion.
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1. Introduction
1.1. Breast cancer
Breast carcinoma is one of the most frequently diagnosed cancers among women worldwide
with a high frequency reported in the West [1, 2]. This highest incidence of breast cancer in
American whites and in most European countries reveal the long-standing high prevalence of
reproductive factors associated with increased risk of breast cancer, including early menarche,
late child bearing age, few pregnancies, hormone replacement therapy and increased mam-
mography [3, 4]. In Israel, the increased incidence of breast cancer may reflect the dispropor-
tionately high prevalence of BRCA1 and BRCA2 mutations [5, 6].
Western lifestyle is another most important factor for Britain’s high number of breast cancer
cases fuelled by the women overeating, too much drinking and too little exercise doing in
routine life. In addition, breastfeeding is also an important factor, which reduces the chance
of developing breast cancer. Eastern women do not drink alcohol than women in the United
Kingdom, and obesity ratio is much lower in Asian women than in western women, whereas
breastfeeding rates are much higher in Asians (http://www.dailymail.co.uk/news/article-
1301445/Western-lifestyle-blame-soaring-breast-cancer-rates.html). Affected women with
breast cancer are usually young and often present with advanced disease [7]. According to a
World Health Organization (WHO) estimate, around 25.2% people are diagnosed with breast
cancer annually. The exact reason why a woman develops breast cancer is still unrevealed;
though certain risk factors enhance a person’s probability of getting breast cancer.
The factors that play a significant role in the aetiology of breast cancer include genetic [8, 9],
hormonal [10, 11], environmental [12], lifestyle [13] and reproductive factors [14]. In addition,
ovarian hormones (endogenous estrogen) are the key risk factors for the development of breast
cancer and their progression among post-menopausal women [15, 16]. However, it is unclear
that to what degree the effects of other risk factors may be mediated by their links with
circulating free estradiol. Intake of vegetables and fruits are related with a substantial decrease
of breast cancer risk [17, 18]. Vegetables are rich in antioxidants and certain phytochemicals
may contribute to the reduced risk of breast cancer [19–21]. Plant-based diets are also high in
fibres, which can decrease serum estrogen and could, in this way, contribute to reduced risk
of breast cancer [22, 23]. In addition, increased consumption of fruit and vegetables are
associated with lower rates of obesity, which is a crucial risk factor for post-menopausal breast
cancer [24]. High energy intake, physical sluggishness, high body mass index (BMI) and weight
put on are coupled to an increased breast [25] cancer risk. Low levels of HDL-C in breast cancer
patients than in control subjects have also been documented [26]. But still, data from prospec-
tive studies are very limited (Moorman, 1998). Furthermore, consanguineous marriages are
common in certain racial groups, which will increases the risk of breast cancer [27].
Among these contributing factors, vitamin D and its receptor gene polymorphisms may play
a pivotal role in the development of mammary gland tumourigenesis [28].
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1.2. Vitamin D and vitamin D receptor (VDR)
Vitamin D and VDR are the two most important participants playing a key role in vitamin D
endocrine system in the prevention of breast cancer. Vitamin D is a sunshine vitamin, which
is involved in a variety of actions and also reduces the risk of many cancers [29, 30].
VDR is a member of nuclear receptor (NR) superfamily and transcription regulating factor also
called NR1I1 or nuclear receptor subfamily 1, group I and member 1. VDR is a high-affnity,
low-capacity receptor having a molecular weight of about 48–55 kD. VDR is expressed in
majority of human tissues. But some cells have decrease or no VDR expression including RBCs,
mature cardiac and skeletal muscles and cerebellar Purkinje cells [31]. Its actions are preceded
by the formation of heterodimer with retinoid X receptor (RXR), which causes the conforma-
tional changes in VDR and allow the binding of vitamin D3 at ligand binding domain (LBD).
In addition, the heterodimer complex then binds with a specific sequence present in the DNA
called vitamin D response element (VDRE). Genomic pathway involves the expression of genes
in a tissue-specific manner [28].
1.2.1. VDR domains
VDR contain five functional domains (Figure 1) including:
1. A and B domains both are shortest domains contain 20 amino acids.
2. C domain (DNA binding domain or DBD) having two Zn fingers [32] motifs. Two alpha
helices are found at the carboxy terminus of each Zn finger (namely helix A and B which
constitutes DNA recognition and phosphate binding sites respectively).
3. Flexible hinge D domain is present in between C and E domains having the ability to
change structural conformation after VDR ligand binding.
4. E domain (ligand binding domain or LBD) consists of 12 alpha helices along with 3 short
beta strands, organized in a manner that it forms three dimensional hormone binding
pockets of which vitamin D3 is attached.
Both N-ter and C-ter has activation function (called AF-2) in translation [33].
1.2.2. Vitamin D/VDR actions
1. Genomic actions: Vitamin D3 produces its pleiotropic effects by genomic and non-
genomic actions. It mediates its genomic actions upon binding to intracellular nuclear
transcription factor called VDR.
2. Non‐genomic actions: Vitamin D also plays various non-genomic actions. Non-genomic
actions are also called rapid actions, which are caused by the interaction of vitamin D with
the membrane VDR to perform its biological effects through intracellular signalling
pathways [35]. However, the contribution of non-genomic pathway in the development
of anti-neoplastic effects on breast remains unclear.
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Figure 1. The crystal structure of VDR showing its functional domains [34]. (A) Schematic representation of VDR do-
mains. (B) LBD of the VDR which contains 12 alpha helices. (C) The binding mode of Vitamin D in the hormone-bind-
ing pocket. (D) The DBD of the Vitamin D. The two zinc atoms are represented in blue in colour, whereas beta sheets
are represented in yellow colour.
2. Bio‐activation and metabolism of Vitamin D in normal breast
It is already known that vitamin D affects the breast cancer cell growth but limited information
is available about its delivery, uptake and metabolism in mammary cells. Vitamin D is either
derived from the gastrointestinal (GIT) absorption or synthesized within the skin under the
exposure of UVB radiations, which then undergoes the 25-hydroxylation in liver in presence
of 25-hydroxylase resulting in the production of 25(OH)D3. 25(OH)D3 is the precursor
molecule for the synthesis of active Vitamin D3 (1,25(OH)2D3). It is a major circulating form
of vitamin D, which is stored in adipose tissues. It is also an accurate biomarker of vitamin D,
which determines the overall status of vitamin D in the body. However, the precursor does not
readily binds to the VDR and must be converted into its active form, 1,25(OH)2D3, which has
high binding affinity to VDR. The conversion of precursor vitamin D into its active metabolite
occurs in the presence of 1-α-hydroxylases. Immunohistochemistry and in situ hybridization
studies indicated strong expression of 1α-hydroxylase protein and mRNA in the distal
convoluted tubule, the cortical and medullary part of the collecting ducts and the papillary
epithelia. Lower expression was observed along the thick ascending limb of the loop of Henle
and Bowman’s capsule. Weaker and more variable expression of 1α-hydroxylase protein and
mRNA was seen in proximal convoluted tubules, and no expression was observed in glomeruli
or vascular structures [36]. Whereas lesser expression of 1α–hydroxylase was also observed in
non–renal cells including keratinocytes, macrophages, prostatic epithelium, colonocytes [37,
38] and breast epithelium [39] to lesser extent. Kidneys and non-renal 1-α-hydroxylases are
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encoded by the same gene mapped on the chromosome 12 [40]. However, the presence of this
enzyme on non-renal tissues indicated that the non-renal tissues have the ability of vitamin D
bio-activation, responsible to convert 25(OH)D3 into 1,25(OH)2D3. 1,25(OH)2D3 is virtually
not detected in human serum under anephric conditions, which means that kidneys are the
major source of 1,25(OH)2D3 in circulation. These observations emphasize that 1,25(OH)2D3
produced by the non-renal tissues is not released in the bloodstream. However, they act locally
upon binding to VDR on the same tissues from where it is synthesized. Such local actions of
vitamin D are likely included in proliferation, differentiation and apoptosis, which are
discussed below in later sections.
2.1. Bio‐activation pathways in breast cells
The above information supports the hypothesis that two distinct pathways may be involved
in the bio-synthesis and bio-activation of vitamin D in breast such as 1,25(OH)2D3 and
25(OH)D3 (vitamin D precursor) pathways [41, 42].
2.1.1. Endocrine pathway
The endocrine pathway is involved with the circulation of 1,25(OH)2D3, which reaches the
mammary tissues and produces anti-neoplastic effects through genomic pathway.
2.1.2. Autocrine/paracrine pathway
The other pathway is the autocrine/paracrine pathway involved with the 25(OH)D3, which
reaches the mammary gland and converts into 1,25(OH)2D3 [43] in the presence of 1-α-
hydroxylase to prevent breast cancer [41]. Most of the extra-renal tissues of the body have its
own 1-α-hydroxylase enzyme needed for the production of active metabolite of vitamin D [37].
The circulating level of 25(OH)D3 seems to be the key regulator of tissue-specific synthesis of
active vitamin D [37, 44]. The locally produced active vitamin D binds with VDRs of mammary
epithelium in order to regulate the expression of more than 200 genes, which are involved in
controlling cell proliferation, inhibit cell growth, stimulate cell differentiation, induce apop-
tosis and inhibit angiogenesis [45] and contribute in the prevention of breast tumourogenesis
[46]. Moreover, mammary epithelial cells also contain 24-hydroxylase enzyme (CYP24), which
converts active vitamin D into less active metabolites including 24,25-dihydrohydroxyvitamin
D3 and 1,24,25-trihydroxyvitamin D3 [43]. For this reason, we can say that breast tissues
contain all the elements of vitamin D signalling axis, which involve in the local synthesis as
well as metabolism of vitamin D and its signal transduction through VDRs.
3. Vitamin D signalling in the prevention of breast cancer
3.1. VDR expression in breast
Several extra-renal epithelial cells of body express VDR, for example, epithelial cells of rat,
mouse and human mammary glands. VDR expression is highest in breast tissues during
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puberty, pregnancy and lactation in women [47]. In mice, the expression is highest in ductal
epithelium when compared to terminal end-buds epithelium of mammary gland. In human,
VDR-positive cells are found in basal and luminal layer of breast epithelium [39]. Cap cells
and stromal compartments of breast are also rich in VDR [48–50]. The presence of VDR in
different cells of breast highlights the complexity of vitamin D signalling in breast tissues.
3.2. Mechanism of vitamin D signalling in breast cancer prevention
Despite these consistent data, the exact mechanism of breast cancer prevention by vitamin D
has yet to be discerned. Both 25(OH)D3 and 1,25(OH)2D3 exert its profound effects on normal
VDR-positive breast epithelium such as hormone-stimulated growth inhibition, ductal
elongation, ductal branching and induction of biomarkers involved in breast differentiation.
The expression of VDR and 1-α-hydroxylase in mammary adipocytes also takes part in the
prevention of cancer in whole tissue since adipocytes secrete diffusible signals in response to
25(OH)D3, which constrain morphogenesis of the nearby ductal tissues [48].
Furthermore, alteration in cellular energy metabolism, immune responses and other processes
of vitamin D signalling in the prevention of breast cancer on non-tumourigenic breast epithe-
lium is described below.
3.2.1. Anti‐proliferation
Vitamin D causes cell-cycle arrest by direct or indirect involvement of growth factors and does
not allow the cell to enter in the S phase from G1 phase [51]. It increases the expression of
cyclin-dependent kinases (CDKs) inhibitors, including p21 and p27, and reduces the expres-
sion of CDK2, CDK4, cyclin D1, cyclin A1 and cyclin E1, which results in the arrest of cell-cycle
progression [52, 53]. It is also involved in the downregulation of c-myc oncoprotein and inhibits
the cell proliferation [54]. However, all these consequences describe that vitamin D hampers
the cell proliferation by affecting the crucial controllers of cell-cycle progression. Furthermore,
vitamin D also enhances the transcription factor CCAT enhancer-binding protein alpha (C/
EBPα), which mediates the anti-proliferative effects of vitamin D observed in in vitro study on
MCF-7 cells [55]. Tumour suppressor TCF-4 also hinder cell-cycle progression [56]. Beside
these, vitamin D also causes the induction of BRCA 1 (breast cancer 1) gene, which is inversely
associated with the cell proliferation, promotes tumour suppression and inhibits cell-cycle
progression [57].
3.2.2. Growth arrest and pro‐apoptosis
Vitamin D plays an important role in the induction of apoptosis in mammary tissues, since in
vitro conditions, such as shrinkage of cell, condensation of chromatin network and fragmen-
tation of DNA, have been observed in MCF-7 cells upon treatment with vitamin D [58]. The
mechanism by which vitamin D induced apoptosis has not been fully understood. However,
the most probable mechanism is the downregulation of anti-apoptotic protein, called Bcl2 (51).
Vitamin D increases the tumour necrotic factor alpha (TNFα) with or without caspase 3
activation. In the caspase 3-independent mechanism, vitamin D-mediated induction of
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apoptosis in MCF-7 cells is thought to be correlated with mitochondrial disruption, which
causes the release of cytochrome C and formation of reactive oxygen species (ROS) resulting
in the apoptosis [59]. Other mechanism of caspase-independent apoptosis induced by vitamin
D-dependent Ca+ absorption is most likely associated with the increased activation of
lysosomal proteases [60]. Finally, vitamin D also acts a pro-oxidant for breast cancer cells,
which generally increase the redox potential [61] of carcinogenic cell, may be one of the most
important underlying pro-aptototic mechanisms of vitamin D. The pro-oxidant action of
vitamin D in MCF-7 cells could result from increased intra-cellular reactive oxygen species
production during aerobic metabolism. Vitamin D inhibits the expression of one of the major
constituents of the cellular defence system against ROS, like superoxide dismutase (SOD) [62].
This decrease could be one of the mechanisms underlying the pro-oxidant action of vitamin
D. Indeed, it was previously reported that overexpression of SOD protects MCF-7 cells from
being injured [63, 64] . Decrease in SOD levels would cause a shift in the balance between
superoxides and hydrogen peroxide (H2O2). Increased levels of superoxides can, in turn, cause
increased oxidative damage attributable to interaction with NO to form the highly toxic
peroxynitrite [65] and to increased availability of free iron that supports hydroxyl radical
formation through the Fenton reaction [66].
Changes in the redox state could translate into reversible oxidation of cysteines in major
proteins that determine cell fate, such as protein kinases, protein tyrosine phosphatases and
transcription factors (e.g. Sp1, activator protein-1, nuclear factor-κB and p53) [67–73]. The key
components of the apoptotic process, such as mitochondrial permeability transition pores and
increase caspases, are also subjected to redox regulation [74]. Oxidation of the cysteine in the
active site of GAPDH may be considered a sensitive, easily accessible marker for these
processes. It is noteworthy that the increase in the cellular redox potential was shown to abolish
the DNA-binding ability of the transcription factors activator protein-1 and nuclear factor-κB
[75] can cause apoptosis and prevent breast cancer. Notably, a recent study describes the
relationship between p53 and VDR. Mutant P53 (mutp53) converts the Vitamin D pro-
apoptotic activity into anti-apoptotic activity and attain oncogenic activity which demonstrate
gain of function (GOF) [76].
3.2.3. Anti‐angiogenesis
Vitamin D inhibits angiogenesis, which is another important feature for tumour growth and
progression. It also has the ability to impede angiogenesis at very minute concentration [77]
mediated through the downregulation of vascular endothelial growth factor (VEGF), tenascin-
C, tumour growth factor α (TGF-α) and epidermal growth factor (EGF) [78, 79].
3.2.4. Anti‐invasion or anti‐metastasis
Vitamin D inhibits the invasion of tumour in nearby tissues but its deficiency promotes the
growth of breast cancer cells in the bones of nude mice and alters the bone micro-environment
[80]. This ability of vitamin D is supposed to be caused by the decrease expression of metal-
loproteinases (MMP-9) and serine proteinases (such as urokinase-type plasminogen activator
and tissue-type plasminogen activator) along with the increased expression of their inhibitors
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[81]. In addition, vitamin D also downregulates P-cadherin [82] and upregulates E-cadherin
[83].
3.2.5. Anti‐inflammation
Vitamin D reduces the expression of cyclooxygenase-2 (COX-2), which plays a crucial role in
the synthesis of prostaglandin in many breast cancer cell lines in human. It increases the
upregulation of 15-hydroxyprostaglandin dehydrogenase, an enzyme which is involved in
catalysing the conversion of active prostaglandins into biologically inactive ketoderivatives
[84]. Prostaglandins have been supposed to play a role in the breast cancer development and
its progression [85]. Prostaglandins are secreted by the breast cancer cells or surrounding
tissues promote tumour progression caused by cell proliferation, resistant to apoptosis,
tumour invasion and angiogenesis [85]. An increased expression of COX-2 in breast cancer has
been assumed to correlate with high-grade, large tumour size and poor prognosis [86].
3.2.6. Anti‐estrogen
Vitamin D inhibits estrogen biosynthesis (steroidogenesis) and its biological actions [84].
Vitamin D suppresses the estrogen pathway by inhibiting the expression of gene which
encodes aromatase (the enzyme which converts androgens to estrogen) [84]. Vitamin D also
reduces the expression of estrogen receptor alpha (ERα-) [87]. The combined actions of vitamin
D can decrease the estrogen and the receptor, which mediates their signalling in the prevention
of breast cancer.
3.3. Vitamin D deficiency and breast cancer
The half-life of circulating vitamin D is approximately about 2–3 weeks which is a better
indicator of blood vitamin D. Active vitamin D3 (1,25(OH)2D3) is locally synthesized from its
precursor (25-(OH)D3) in almost all body cells because of the universal presence of 1α-
hydroxylases in all cell type including breast [88]. So, the deficiency of 1-α hydroxylase may
augment the deficiency of vitamin D and thereby associated with increased breast cancer risk
and mortality [89].
Serum vitamin D concentrations and vitamin D supplementations are the independent
predictors of breast cancer risk. Serum level of vitamin D of more than 50 ng/ml is associated
with the 50% lower risk of breast cancer in women than serum values less than 30 ng/ml [90,
91]. In addition, breast cancer risk reduces in the pre-menopausal women who consume
calcium and vitamin D orally [92]. Locally advanced breast cancer patients have more severe
vitamin D deficiency than those with early-stage disease [93].
Deficiency of vitamin D is related with secondary hyperparathyroidism, which causes
increased bone resorption, release of calcium from bones osteoclasts into the blood and may
exacerbate osteoporosis with subsequent harsh effects on bone mineral density (BMD). In
breast cancer patients, osteopenia and osteoporosis mostly occur because of early menopause
and vitamin D deficiency, which is then augmented by chemotherapy and hormone replace-
ment therapy [94]. Therefore, breast cancer patients are necessary to suffer a baseline metabolic
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bone evaluation along with circulating vitamin D levels and bone mineral densitometry [94,
95].
Vitamin D deficiency is also associated with the recurrence, tumour size and death from breast
cancer. It means that having enough amount of vitamin D may be able to keep a cancer from
getting worse. In fact a recent meta-analysis concluded that high circulating level of vitamin
D is weakly related with breast cancer incident; however, strong association was found with
better breast cancer survival [89]. So, the maintenance of an optimal vitamin D status at the
time of diagnosis and during 1-year follow-up period is necessary for improving survival of
breast cancer patient.
There are four types of studies which illustrated whether exposure of ultraviolet B (UVB)
radiations and low levels of vitamin D decrease the risk of breast cancer.
3.3.1. Geographical studies
In these studies, the geographical variation in the incidence or mortality of breast cancer is
compared statistically with solar UVB radiations. The lower breast cancer incidence rate was
found in the regions of high solar UVB radiations such as in Australia, China, France, Nordic
countries, Spain and the United States [96].
3.3.2. Observational studies
Observational studies do comparison of vitamin D levels with the incidence of breast cancer
among cases and controls. There are two categories of observational studies:
1. The studies in which vitamin D levels is measured near the time of breast cancer diagnosis
are called case-control studies.
2. The studies in which vitamin D is measured at the time of women enrolment in studies
prior to the breast cancer diagnosis are called nested case-control studies.
Only the case-control studies have reported that low levels of vitamin D are associated with
breast cancer risk [97]. The reason why nested case-control studies have not reported the same
results may be due to
1. breast cancer develops very rapidly, and
2. without supplementation, vitamin D levels tend to change little over time.
Observational studies have also documented that those females have higher vitamin D levels
at the time of diagnosis live longer as compared to those with low vitamin D levels [46, 96]. In
addition, the chances of mortality are higher in black women after diagnosis of breast cancer
than in white women.
3.3.3. Laboratory studies
Laboratory studies have focused on the mechanisms of vitamin D in the contribution of
reduced risk of breast and other cancer types. According to these studies, vitamin D allows
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the cells to stay alive if they are the right type and present at the right place, or it helps the cells
to commit suicide (apoptosis) if cells are not the right type or not present at the right place.
Vitamin D also reduces the formation of blood vessels around tumours and decreases the
ability of tumours to invade [98]. According to the randomized controlled trials, vitamin D
reduced the risk of cancer, including breast cancer [99, 100].
4. Vitamin D receptor gene
The human VDR (hVDR) gene is located at long arm of chromosome 12 bands 13-14 (12q13-
14) [101, 102]. The gene is 75 kb long and contains 11 exons [103]. This gene is divided into
three regions: one coding region and two non-coding regions.
4.1. Non‐coding regions
The 5’ promoter region of VDR lacks initiator (TATA and CAAT boxes) and is rich in GC
content. It provides the putative site for binding of many transcription factors [103]. The
promoter region is present at exon 1(1a, 1b, 1c, 1d, 1e, 1f). The promoter region facilitates the
transcription activity of VDR target gene. The 3’ UTR contains poly (A) repeats, which is
reported to be associated with the mRNA stability.
4.2. Coding region
Coding region comprises of exon 2–9. Exon 2, which have translation start codons, contains
DNA-binding site, whereas exon 7, 8 and 9 have ligand (vitamin D) binding site [104].
5. Single nucleotide polymorphism (SNP)
Polymorphism is defined as the presence of two or more clearly different phenotypic variants
of a particular DNA sequence in the same population of a species. The most common form of
polymorphism is the single nucleotide polymorphism in which variation occurs at a single
base pair usually present in approximately 1% of the population. These types of changes can
be present in non-coding region of genes and in introns, which would not affect the translation
of proteins, but these changes can affect the degree of gene expression and levels of proteins.
The changes can also be present in coding regions of DNA or exons resulting in the formation
of an altered protein sequence. Sometimes variation in exons do not cause the change in the
structure of protein called synonymous polymorphisms.
These changes often produce or eliminate restriction sites for endonuclease to digest the DNA.
As a result, fragments of DNA with a different length will be obtained which can be identified
by gel electrophoresis. This process is called restriction fragment length polymorphisms
(RFLPs). The produced fragments will be the undigested fragments, which is homozygous
dominant, whereas the digested fragments are heterozygous and homozygous recessive.
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Sometimes polymorphic alleles are linked with each other and within a population in non-
random proportion is known as linkage disequilibrium (LD), [105] and the combination of
alleles (blocks) or set of SNPs present on the same chromosome which tends to be inherited
together is termed as haplotype. The size of these blocks is different ranging between 10 and
20 kb and could be important in determining the reason of genetic disorder.
6. SNPs in the VDR gene
The variation in the 5’-promoter region of VDR gene can change the sequence of mRNA as
well as protein levels, whereas alteration in 3’ UTR sequence can disturb the stability of mRNA
thereby affecting the efficacy of translated protein. Some SNPs have been existed in the VDR
gene, including Cdx2 [106], Fok1 [107], Bsm1, Taq1, EcoRV [108], Apa1 [101] and poly (A) [109]
microsatellite repeats.
6.1. Cdx2 SNP
The VDR Cdx2 (G-1739A) is the single nucleotide polymorphism, which was recognized by
the sequence analysis of promoter region. It is an adenine to guanine (A to G) SNP situated at
the promoter region of VDR gene at exon 1e. It was initially reported to be located at the 3731
bp upstream exon 1a of promoter region of VDR gene among Japanese women [106], but later
identified to be located at 1739 kbp upstream of 1e exon just 2 kb away from the exon 1a among
many ethnic population [110]. It is the binding region of Cdx2 protein, a most important
intestine-specific caudal-related homeodomain protein, which increases the transcription of
VDR. When A allele is present in Cdx2 promoter, the Cdx2 protein is bound more strongly as
compared to when a G allele is present. The A allele stimulates the initiation of transcription,
whereas G allele inhibits [106].
6.2. GATA SNP
GATA (A-1012G) is located at exon 1a in the core sequence of DNA called AGATAT [111]. It
provides the binding of GATA protein and the binding site is present in A allele and absent in
G allele. The mechanism of this polymorphism is not identified yet; however, this polymor-
phism alters the immune responses to cancer cells. A allele is responsible to reduce cytotoxic
response to cancer cells. In addition, it is also an important element that if the transcription is
begun in exon 1a or 1d. In presence of G allele, exon 1d comprises an alternate start codon
which results in a formation of N-ter extended protein called VDRB1. G allele is most likely
associated with the VDRB1 (long) protein, whereas A allele is related with the VDRA (short)
protein.
6.3. Fok1 SNP
Fok1 polymorphism is also called start codon polymorphism (SCP). It is a thymine to cytosine
(ATG to ACG) polymorphism located at the 10 bp upstream 5’ end of exon 2 on the DNA-
Vitamin D, Its Receptor Gene Polymorphism and Breast Cancer
http://dx.doi.org/10.5772/64505
145
binding domain, which results in a formation of more active transcription factor that is three
amino acids shorter [103, 112]. Those individuals who have ACG sequence in the start codon,
the initiation of translation occurs at the second ATG site which results in a formation of three
less amino acids at NH2 terminus containing 424 amino acids. If the initiation occurs at first
ATG sequence, it produces full-length VDR protein containing 427 amino acids. In the presence
of restriction site, alleles are designated as ‘f’, whereas its absence is designated as ‘F’ (active
form) [113]. The restriction recognition site of Fok1 is 5’-GGATG*-3’; 3’-CCTAC*-5’ and enzyme
cleaves 9/13 nucleotide downstream of the recognition site.
6.4. Bsm1‐Apa1‐Taq1 SNP
Most of the functional sequence variants identified near the 3’ region of VDR gene were Bsm1,
Apa1 and Taq1 SNP. These SNPs are in linkage disequilibrium with each other and are located
in the same haplotype block. Therefore, these SNPs may have the potential to influence the
mRNA stability. The Apa1 and Bsm1 are located at intron 8, whereas Taq1 is located at exon 9
[114].
The presence of restriction enzyme site in these SNPs is designated as lower case letter such
as b, a and t, whereas absence is designated as upper case letter including B, A, T. The re-
striction site for Bsm1 is 5’-GAATGCN*-3’, Apa1 is 5’-GGGCC*C-3’ and Taq1 is 5’-T*CGA-
3’.
6.5. Poly (A) repeats
Poly (A) tail is a variable number of tandem repeats (VNTR) or short tandem repeats (STR)
containing variable numbers of adenine nucleotide present at the 3’ UTR of VDR. Poly (A) is
also linked with Bsm1, Apa1 and Taq1 polymorphisms and also involved in the mRNA stability
of VDR. It varies in length and can be divided into two types:
1. The long (L) Poly (A) sequence in which 18–24 adenine nucleotide is present, and
2. The short (S) Poly (A) sequence in which 13–17 adenine nucleotide is present.
Because all four polymorphisms (Bsm1, Apa1, Taq1 and Poly (A)) are present in close proximity
on the VDR gene, strong linkage disequilibrium exists among them. The two most common
haplotypes are:
1. baTL haplotype in which Bsm1 and Apa1 restriction sites are present, whereas Taq1 site is
absent along with the presence of long Poly (A) repeats.
2. BAtS haplotype Bsm1 and Apa1 restriction sites are absent, whereas Taq1 site is absent
along with the presence of short Poly (A) repeats [115].
The baTL haplotype is reported to be associated with the increase incidence of breast cancer
[116].
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7. VDR gene polymorphisms and breast cancer
VDR gene polymorphism is associated with the breast cancer risk [117–125] but insufficient
data are available to find the relationship with breast cancer risk [126]. The studies have pointed
out allelic variations in VDR gene, such as Cdx2, Fok1, Bsm1, Taq1, Apa1 and Poly A in different
ethnic groups with breast cancer incidence with contradictory results [117, 118, 121, 126].
7.1. Cdx2 polymorphism and breast cancer
The contradictory observations were reported on the association of Cdx2 polymorphism and
breast cancer susceptibility [125]. Recently, a meta-analysis has documented that Cdx2
polymorphism is linked with breast cancer susceptibility only in Africans [127]. However, no
profound relations was observed between Cdx2 polymorphism and breast cancer risk among
Pakistani population [126].
7.2. Fok1 polymorphism and breast cancer
Fok1 polymorphism contain large consensus sequence has no relationship with breast cancer
incidence [116, 117]. But the association between Fok1 polymorphism and breast cancer was
reported in several ethnic groups [113, 120], mainly in Caucasians [128, 129]. Nemenqani et al.
[121] found that Fok1 polymorphism is associated with the ER and PR status of breast cancer
and described that Fok1 polymorphism has a significant interaction with the ER status but not
with PR status of breast cancer.
7.3. Bsm1 polymorphism and breast cancer
Bsm1 polymorphism is the most important functional VDR gene polymorphism, which is
found to be associated with the risk of developing breast cancer [124]. However, it has also
been documented that there is no relation between Bsm1 and breast cancer [119]. Rollison et
al. [123] describe that Bsm1 is involved to alter the vitamin D intake and overall breast cancer
risk. McCullough et al. [130] found that B allele of Bsm1 decreases breast cancer incidence by
20%.
7.4. Taq1 polymorphism and breast cancer
Many case-control studies suggested that Taq1 polymorphism is not associated with breast
cancer risk [119–121]. But it has been reported that Taq1 is one of the functional polymorphisms
which is linked with increased breast cancer incidence [131, 132]. A meta-analysis on large
ethnic groups revealed that the Taq1 polymorphism increases the risk of breast cancer devel-
opment in Caucasians; however, no profound association was observed among Asians [133].
7.5. Other polymorphisms and breast cancer
Positive association of poly A [118] or Apa1 [119] was found to be reported with breast cancer
risk, showing a connection between polymorphism and likelihood of having a tumour.
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8. Conclusion
This chapter concluded that women with breast cancer are more likely to have low vitamin D
levels. Those women who do not get adequate vitamin D may be more likely to develop breast
cancer later in life as compared to those who have higher vitamin D levels, who are less likely
to develop breast cancer and less likely to die from breast cancer.
Because of the broad spectrum of vitamin D effects on mammary tissue, it is suggested to be
a most important physiological growth regulator of mammary gland and could be a potential
therapeutic agent. Additionally, due to the expression of VDR to a higher extent on breast
epithelial cells, vitamin D signalling should also be monitored during breast cancer treatment.
Since breast cancer is a complex disease which may or may not be associated with the decreased
vitamin D levels or VDR polymorphisms. However, the functions and role of vitamin D and
VDR cannot be neglected during breast cancer treatment.
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